Albireo has completed the Phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation.
In addition, the data revealed appropriate efficacy signals in this patient population. A3309 is developed for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome (IBS-C).
Based on these results, Albireo expects to recruit 180 patients with chronic idiopathic constipation in a US Phase 2b study under an IND approved by the FDA.
A3309 is a therapeutic alternative with a novel mechanism of action developed for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome (IBS-C). A3309 modulates the re-uptake of bile acids by inhibiting the ileal bile acid transporter.